153 related articles for article (PubMed ID: 8258993)
21. Identification of the antigenic epitopes in staphylococcal enterotoxins A and E and design of a superantigen for human cancer therapy.
Erlandsson E; Andersson K; Cavallin A; Nilsson A; Larsson-Lorek U; Niss U; Sjöberg A; Wallén-Ohman M; Antonsson P; Walse B; Forsberg G
J Mol Biol; 2003 Nov; 333(5):893-905. PubMed ID: 14583188
[TBL] [Abstract][Full Text] [Related]
22. Perforin and IFN-gamma are involved in the antitumor effects of antibody-targeted superantigens.
Rosendahl A; Kristensson K; Hansson J; Riesbeck K; Kalland T; Dohlsten M
J Immunol; 1998 Jun; 160(11):5309-13. PubMed ID: 9605129
[TBL] [Abstract][Full Text] [Related]
23. Activation of human T cells with NK cell markers by staphylococcal enterotoxin A via IL-12 but not via IL-18.
Ami K; Ohkawa T; Koike Y; Sato K; Habu Y; Iwai T; Seki S; Hiraide H
Clin Exp Immunol; 2002 Jun; 128(3):453-9. PubMed ID: 12109440
[TBL] [Abstract][Full Text] [Related]
24. Endothelial cells expressing an inflammatory phenotype are lysed by superantigen-targeted cytotoxic T cells.
Riesbeck K; Billström A; Tordsson J; Brodin T; Kristensson K; Dohlsten M
Clin Diagn Lab Immunol; 1998 Sep; 5(5):675-82. PubMed ID: 9729535
[TBL] [Abstract][Full Text] [Related]
25. T-cell stimulation and cytokine release induced by staphylococcal enterotoxin A (SEA) and the SEAD227A mutant.
Holzer U; Orlikowsky T; Zehrer C; Bethge W; Dohlsten M; Kalland T; Niethammer D; Dannecker GE
Immunology; 1997 Jan; 90(1):74-80. PubMed ID: 9038715
[TBL] [Abstract][Full Text] [Related]
26. Immunopharmacology of the superantigen staphylococcal enterotoxin A in T-cell receptor V beta 3 transgenic mice.
Dohlsten M; Björklund M; Sundstedt A; Hedlund G; Samson D; Kalland T
Immunology; 1993 Aug; 79(4):520-7. PubMed ID: 7691731
[TBL] [Abstract][Full Text] [Related]
27. Phage-selected primate antibodies fused to superantigens for immunotherapy of malignant melanoma.
Tordsson JM; Ohlsson LG; Abrahmsén LB; Karlström PJ; Lando PA; Brodin TN
Cancer Immunol Immunother; 2000 Mar; 48(12):691-702. PubMed ID: 10752477
[TBL] [Abstract][Full Text] [Related]
28. Genetically engineered superantigens as tolerable antitumor agents.
Hansson J; Ohlsson L; Persson R; Andersson G; Ilbäck NG; Litton MJ; Kalland T; Dohlsten M
Proc Natl Acad Sci U S A; 1997 Mar; 94(6):2489-94. PubMed ID: 9122222
[TBL] [Abstract][Full Text] [Related]
29. Functional characterization of the interaction between the superantigen staphylococcal enterotoxin A and the TCR.
Antonsson P; Wingren AG; Hansson J; Kalland T; Varga M; Dohlsten M
J Immunol; 1997 May; 158(9):4245-51. PubMed ID: 9126986
[TBL] [Abstract][Full Text] [Related]
30. T cell- and perforin-dependent depletion of B cells in vivo by staphylococcal enterotoxin A.
Sundstedt A; Grundström S; Dohlsten M
Immunology; 1998 Sep; 95(1):76-82. PubMed ID: 9767460
[TBL] [Abstract][Full Text] [Related]
31. Repeated treatment with antibody-targeted superantigens strongly inhibits tumor growth.
Rosendahl A; Kristensson K; Hansson J; Ohlsson L; Kalland T; Dohlsten M
Int J Cancer; 1998 Apr; 76(2):274-83. PubMed ID: 9537591
[TBL] [Abstract][Full Text] [Related]
32. Antibody-targeted superantigens induce lysis of major histocompatibility complex class II-negative T-cell leukemia lines.
Ihle J; Holzer U; Krull F; Dohlsten M; Kalland T; Niethammer D; Dannecker GE
Cancer Res; 1995 Feb; 55(3):623-8. PubMed ID: 7530598
[TBL] [Abstract][Full Text] [Related]
33. T-cell immunotherapy for human MK-1-expressing tumors using a fusion protein of the superantigen SEA and anti-MK-1 scFv antibody.
Ueno A; Arakawa F; Abe H; Matsumoto H; Kudo T; Asano R; Tsumoto K; Kumagai I; Kuroki M; Kuroki M
Anticancer Res; 2002; 22(2A):769-76. PubMed ID: 12014649
[TBL] [Abstract][Full Text] [Related]
34. Intercellular adhesion molecule-1 and leukocyte function-associated antigen-3 provide costimulation for superantigen-induced T lymphocyte proliferation in the absence of a specific presenting molecule.
Lamphear JG; Stevens KR; Rich RR
J Immunol; 1998 Jan; 160(2):615-23. PubMed ID: 9551895
[TBL] [Abstract][Full Text] [Related]
35. Superantigens anergize cytokine production but not cytotoxicity in vivo.
Sundstedt A; Dohlsten M; Hedlund G; Höidén I; Björklund M; Kalland T
Immunology; 1994 May; 82(1):117-25. PubMed ID: 7913912
[TBL] [Abstract][Full Text] [Related]
36. Locally superantigen-activated peritoneal cytolytic T lymphocytes belong to the CD8+ CD45RC- subset and lyse MHC class II+ tumor cells.
Hansson J; Ericsson PO; Dohlsten M; Sjögren HO; Kalland T; Hedlund G
Immunol Lett; 1992 Dec; 34(3):229-36. PubMed ID: 1487309
[TBL] [Abstract][Full Text] [Related]
37. Superantigen-induced lysis of melanoma cells.
Krull F; Holzer U; Ihle J; Bethge W; Fierlbeck G; Kalland T; Dohlsten M; Niethammer D; Dannecker GE
Melanoma Res; 1997 Jun; 7(3):214-22. PubMed ID: 9195560
[TBL] [Abstract][Full Text] [Related]
38. Monotherapeutically nonactive CTLA-4 blockade results in greatly enhanced antitumor effects when combined with tumor-targeted superantigens in a B16 melanoma model.
Sundstedt A; Celander M; Eriksson H; Törngren M; Hedlund G
J Immunother; 2012 May; 35(4):344-53. PubMed ID: 22495392
[TBL] [Abstract][Full Text] [Related]
39. Tumor-targeted superantigens produce curative tumor immunity with induction of memory and demonstrated antigen spreading.
Azulay M; Shahar M; Shany E; Elbaz E; Lifshits S; Törngren M; Friedmann A; Kramer R; Hedlund G
J Transl Med; 2023 Mar; 21(1):222. PubMed ID: 36967382
[TBL] [Abstract][Full Text] [Related]
40. Phase I study of single, escalating doses of a superantigen-antibody fusion protein (PNU-214565) in patients with advanced colorectal or pancreatic carcinoma.
Nielsen SE; Zeuthen J; Lund B; Persson B; Alenfall J; Hansen HH
J Immunother; 2000 Jan; 23(1):146-53. PubMed ID: 10687147
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
